There is 1 paper on ALPK2 in aging research: none in people yet, 1 in animals.
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Hori Sciences And Arts Foundation and 2 more
- Animals1
Effects
3Cardiac stiffness
downin mice1
1 study
Cardiac stiffness
downin mice1
ALPK2 decreases cardiac stiffness in mice (Alpk2 overexpression in HFpEF).
“Alpk2 overexpression increased the phosphorylation of tropomyosin 1, a major regulator that binds myosin to actin, and mitigated cardiac stiffness in HFpEF.”
AnimalsAlpk2 overexpression in HFpEFheart
ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Tropomyosin 1 phosphorylation
upin mice1
1 study
Tropomyosin 1 phosphorylation
upin mice1
ALPK2 increases tropomyosin 1 phosphorylation in mice (Alpk2 overexpression in HFpEF).
“Alpk2 overexpression increased the phosphorylation of tropomyosin 1”
AnimalsAlpk2 overexpression in HFpEFheart
ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Cardiac systolic dysfunction
no changein mice1
1 study
Cardiac systolic dysfunction
no changein mice1
ALPK2 showed no clear effect on cardiac systolic dysfunction in mice.
“Alpk2 deficiency did not affect cardiac systolic dysfunction in the myocardial infarction model or the pressure-overload-induced heart failure model.”
Animalsshown by Alpk2 knockout in myocardial infarction and pressure-overload-induced heart failure modelsheart
ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction
FASEB journal : official publication of the Federation of American Societies for Experimental Biology